18F-氟吡啶哒嗪PET与SPECT心肌灌注显像诊断效能的系统评价与荟萃分析
该系统评价与荟萃分析比较了18F-氟吡啶哒嗪PET与SPECT心肌灌注显像在检测冠状动脉疾病中的诊断效能,共纳入3项试验、1476例患者。结果显示,18F-氟吡啶哒嗪PET在≥50%和≥70%狭窄的敏感性均高于SPECT,特异性略低或相当,且在肥胖女性和女性亚组中敏感性优势更明显;同时其图像质量更优、辐射剂量更低。但研究数量有限,结论需谨慎解读。
要点
- 18F-氟吡啶哒嗪PET诊断CAD的敏感性高于SPECT,特异性略低。
- 在BMI≥30kg/m²和女性亚组中,PET的敏感性优势更突出。
- PET静息和负荷图像质量更优,且辐射剂量更低。
核心结论
- 18F-氟吡啶哒嗪PET较SPECT心肌灌注显像敏感性更高、辐射剂量更低且图像质量更优。
- 在女性和高BMI患者中,PET的敏感性优势尤为明显,而亚组特异性相当。
主要发现
- 对于≥50%狭窄,PET汇总敏感性/特异性为76%(95%CI 71-81%)/71%(63-78%),SPECT为61%(53-69%)/76%(60-86%)。
- 对于≥70%狭窄,PET汇总敏感性/特异性为87%(77-94%)/63%(52-73%),SPECT为73%(62-81%)/72%(50-87%)。
- 在BMI≥30kg/m²患者中,PET敏感性/特异性为74%(68-78%)/73%(64-80%),SPECT为61%(49-72%)/75%(56-88%)。
- 在女性中,PET敏感性/特异性为73%(57-84%)/76%(70-81%),SPECT为50%(29-70%)/78%(60-90%)。
- 静息和负荷图像质量均支持PET更优(RR 1.29[1.19-1.41]和1.14[1.11-1.17],均p<0.00001),且辐射剂量更低。
关键数值与推荐
- 以有创冠状动脉造影为参考标准,分别评估≥50%和≥70%狭窄的诊断效能。
临床怎么用
- 对于女性或高BMI疑似CAD患者,可优先考虑18F-氟吡啶哒嗪PET心肌灌注显像以利用其更高的敏感性。
- 在需要降低辐射剂量或优化图像质量时,18F-氟吡啶哒嗪PET较SPECT具有优势。
局限性
- 纳入研究数量有限,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to synthesise diagnostic evidence comparing a novel myocardial perfusion radiotracer [¹⁸F]flurpiridaz PET with SPECT myocardial perfusion imaging (MPI) in detecting coronary artery disease (CAD). METHODS: A systematic search to Feb 2026 was conducted in Web of Science, Scopus, PubMed, and the Cochrane Library. Studies comparing [¹⁸F]flurpiridaz PET with SPECT/MPI were screened. Primary outcomes were sensitivity and specificity using invasive coronary angiography as the reference standard. Secondary outcomes included image quality and radiation dose. RESULTS: Out of 558 studies, 28 publications were fully screened, and three trials comparing [¹⁸F]flurpiridaz PET with [⁹⁹ᵐTc]Tc-sestamibi/tetrofosmin SPECT were identified (1476 patients). For ≥ 50% stenosis, pooled sensitivity/specificity were 76% (95% CI 71-81%)/71% (63-78%) for flurpiridaz PET and 61% (53-69%)/76% (60-86%) for SPECT; for ≥ 70% stenosis, values were 87% (77-94%)/63% (52-73%) versus 73% (62-81%)/72% (50-87%), respectively. In patients with BMI ≥30kg/m², sensitivity/specificity were 74% (68-78%)/73% (64-80%) for flurpiridaz PET and 61% (49-72%)/75% (56-88%) for SPECT. In women, sensitivity/specificity were 73% (57-84%)/76% (70-81%) for flurpiridaz PET versus 50% (29-70%)/78% (60-90%) for SPECT. Rest and stress image quality favoured flurpiridaz PET (RR1.29[1.19-1.41] and 1.14[1.11-1.17], both p<0.00001) with superior image quality and lower radiation dose. CONCLUSION: This first meta-analysis suggests higher sensitivity of [¹⁸F]flurpiridaz PET vs SPECT MPI with significantly lower radiation dose and improved image quality. [¹⁸F]flurpiridaz is especially useful for assessing women and patients with high BMI, given its superior sensitivity and comparable subgroup specificity. However, findings should be interpreted cautiously due to the limited number of studies.
引用
- Kashbour M, Amro S, Nada EA, et al. Comparative diagnostic performance of [18F] flurpiridaz PET and SPECT myocardial perfusion imaging (MPI): a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42474502. doi:10.1007/s00259-026-07949-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。